Regulatory tracker

Regulation (EU) 2017/745

EU framework governing the placing on the market and conformity of medical devices. A targeted MDR/IVDR simplification revision (COM(2025) 1023) is before Parliament and Council. The legacy-device dates below, marked conditional, apply only to devices that meet the conditions of Art. 120(3c) MDR as amended by Reg (EU) 2023/607.

• 5 April 2017: Signed by Parliament and Council Source
• 26 May 2021: Date of application Source
• 16 December 2025: Targeted MDR/IVDR simplification proposed (COM(2025) 1023) Source
• 28 May 2026: First four modules of the European database on medical devices (EUDAMED) mandatory (Reg (EU) 2024/1860) Source
• 31 December 2027: Legacy transition ends for class III and class IIb implantable devices, except listed IIb implants such as screws and plates (conditional) Source
• 31 December 2028: Legacy transition ends for other class IIb, class IIa, Is and Im devices, and for self-declared devices that now need a notified body (conditional) Source

• EU MDR Compliance for Swiss MedTech: The Dual-Track Reality
• EU Authorized Representatives for Swiss Manufacturers Under the MDR and IVDR
• Clinical Evidence for SaMD: What Swiss and EU Regulators Actually Expect
• Post-Market Surveillance for SaMD: When Software Keeps Changing

SR 812.213

Swiss medical devices ordinance, aligned with but distinct from the EU MDR; legacy-device transition periods mirror Reg (EU) 2023/607 since November 2023.

• 1 July 2020: Adopted by the Federal Council Source
• 26 May 2021: Entry into force (revised) Source
• 1 November 2023: Transition-period alignment with Reg (EU) 2023/607 in force Source

• Swiss MedTech Export Without the MRA: What Third-Country Status Requires

BBl 2026 615 (Federal Council dispatch, Geschäft 26.023); signed 2 March 2026, ratification pending

Signed treaty package updating the bilateral agreements between Switzerland and the EU. Its institutional protocol obliges both sides to incorporate EU acts within the scope of the Mutual Recognition Agreement (MRA) into its Annex 1 as soon as possible, by decision of the Joint Committee. The medical-devices chapter is to be updated that way once the package is in force; Switzerland remains a third country under the MDR and IVDR at least until that Joint Committee decision takes effect.

• 2 March 2026: Package signed Source
• 13 March 2026: Federal Council dispatch (Botschaft) adopted Source

• Swiss MedTech Export Without the MRA: What Third-Country Status Requires

Regulation (EU) 2017/746

EU framework for in vitro diagnostic medical devices. Transitional periods restructured by Regulation (EU) 2024/1860; a targeted MDR/IVDR simplification revision (COM(2025) 1023) is before Parliament and Council. The legacy-device dates below, marked conditional, apply only to devices that meet the conditions of Art. 110(3c) IVDR as amended by Reg (EU) 2024/1860.

• 5 April 2017: Signed by Parliament and Council Source
• 26 May 2022: Date of application Source
• 26 May 2025: Deadline to have a quality management system (QMS) under Art. 10(8) IVDR in place, a condition of the extended transition Source
• 16 December 2025: Targeted MDR/IVDR simplification proposed (COM(2025) 1023) Source
• 31 December 2027: Legacy transition ends for all Directive-certified devices and for self-declared class D devices (conditional) Source
• 31 December 2028: Legacy transition ends for self-declared class C devices (conditional) Source
• 31 December 2029: Legacy transition ends for self-declared class B and sterile class A devices (conditional) Source
• 31 December 2030: Health institutions must justify each in-house device by showing that no equivalent device on the market meets the target patient group's needs (Art. 5(5)(d) IVDR, deferred by Reg (EU) 2024/1860) Source

• Software as a Medical Device (SaMD): Classification Pitfalls in Switzerland and the EU

SR 812.219

Swiss in vitro diagnostics ordinance mirroring the EU IVDR. The January 2025 amendment mirrors the transition extensions of Reg (EU) 2024/1860 and defers to 31 December 2030 the duty of health institutions to justify each in-house device by showing that no equivalent device on the market meets the need.

• 4 May 2022: Adopted by the Federal Council Source
• 26 May 2022: Entry into force Source
• 1 January 2025: Transition-alignment amendment in force (mirrors Reg (EU) 2024/1860) Source
• 31 December 2030: Health institutions must justify each in-house device by showing that no equivalent device on the market meets the target patient group's needs Source

Regulation (EU) 2016/679

EU data protection regime for the processing of personal data. The Digital Omnibus (data) proposal of November 2025 (COM(2025) 837) would amend it; it is still before Parliament and Council and has not been adopted.

• 27 April 2016: Signed by Parliament and Council Source
• 25 May 2018: Date of application Source
• 19 November 2025: Digital Omnibus (data) amendment proposed (COM(2025) 837) Source

• Data Privacy in Clinical Trials: GDPR Meets DSG

SR 235.1

Swiss federal data protection act (revised).

• 25 September 2020: Adopted by Parliament (final vote) Source
• 1 September 2023: Revised act in force Source

• Data Privacy in Clinical Trials: GDPR Meets DSG

Regulation (EU) 2025/327

EU framework for electronic health data: access and exchange for patient care, including across borders (primary use), and reuse for research, innovation and policy-making (secondary use), with obligations for manufacturers of electronic health record (EHR) systems.

• 11 February 2025: Signed by Parliament and Council Source
• 25 March 2025: Entry into force Source
• 26 March 2027: General application; core implementing acts due Source
• 26 March 2027: Member States name their digital health authorities, health data access bodies and national contact points, and notify their penalty rules (Art. 19, Art. 23, Art. 55, Art. 75 and Art. 99 EHDS) Source
• 26 March 2029: Primary-use rules apply to the first priority data categories (patient summaries, electronic prescriptions and dispensations); secondary-use rules apply to most data categories Source
• 26 March 2031: Primary-use rules extend to medical imaging studies, test results and discharge reports; secondary-use rules extend to the remaining data categories, including genomic data Source

SR 816.1

Swiss electronic patient record act. A total revision, the EGDG (Bundesgesetz über das elektronische Gesundheitsdossier: an electronic health record with an opt-out model on a single federal platform), is before Parliament; the new system is planned to operate from around 2030.

• 19 June 2015: Adopted by Parliament (final vote) Source
• 15 April 2017: Entry into force Source
• 5 November 2025: Federal Council dispatch on the EGDG (total revision) adopted Source

Regulation (EU) 2023/2854

EU horizontal rules on access to connected-product data, business-to-business data sharing, and cloud switching.

• 13 December 2023: Signed by Parliament and Council Source
• 11 January 2024: Entry into force Source
• 12 September 2025: Main obligations apply Source
• 12 September 2026: Access-by-design duty for newly marketed connected products (Art. 3(1) Data Act) Source
• 12 September 2027: Unfair-terms rules extend to pre-existing long-term contracts Source

• Cloud Service Contracts: Jurisdictional Complexity

Directive (EU) 2022/2555

EU directive raising cybersecurity obligations for essential and important entities; technical requirements for digital-infrastructure entities specified by Implementing Regulation (EU) 2024/2690. Four Member States (Ireland, Spain, France and the Netherlands) were referred to the Court of Justice on 8 July 2026 over missing transposition (Commission press release IP/26/1499).

• 14 December 2022: Signed by Parliament and Council Source
• 17 October 2024: Member-State transposition deadline Source

• NIS2 for Connected Medical Devices: Cybersecurity Requirements and Implications

SR 128

Swiss information security act, including the duty of critical-infrastructure operators to report cyberattacks to the Federal Office for Cybersecurity (BACS) within 24 hours of discovery. Its staged entry into force was completed on 1 October 2025. The Federal Council intends to move this reporting duty into a separate cybersecurity act (Cybersicherheitsgesetz, CSG), which is also to set cybersecurity requirements for hardware and software products, oriented on the EU Cyber Resilience Act; a consultation draft is due by June 2027.

• 18 December 2020: Adopted by Parliament (final vote) Source
• 1 January 2024: Entry into force (staged) Source
• 1 April 2025: Reporting duty in force: critical-infrastructure operators must report cyberattacks to the Federal Office for Cybersecurity (BACS) within 24 hours of discovery Source
• 1 October 2025: Reporting-duty sanctions in force Source
• 25 September 2026: Federal Council mandated a consultation draft, due by June 2027, for a separate cybersecurity act (Cybersicherheitsgesetz, CSG) Source

• Cybersecurity for SaMD: Meeting MDR and Beyond

Regulation (EU) 2024/2847

EU regulation on horizontal cybersecurity requirements for products with digital elements. Its notified-body rules (Art. 35–51 CRA) have applied since 11 June 2026 and its reporting obligations (Art. 14 CRA) since 11 September 2026; its main obligations apply from 11 December 2027.

• 23 October 2024: Signed by Parliament and Council Source
• 10 December 2024: Entry into force Source
• 11 June 2026: Notified-body framework applies (Art. 35–51 CRA) Source
• 11 September 2026: Reporting obligations (Art. 14 CRA) apply Source
• 11 December 2027: Main obligations apply Source

• Cybersecurity for SaMD: Meeting MDR and Beyond

Regulation (EU) 2024/1689

EU horizontal regulation on artificial intelligence, applying risk-tiered obligations. The Digital Omnibus on AI (Regulation (EU) 2026/1744, in force since 27 July 2026) defers the high-risk obligations for standalone systems under Annex III AI Act to 2 December 2027 and for product-embedded systems under Annex I AI Act to 2 August 2028. Transparency obligations (Art. 50 AI Act) applied on schedule on 2 August 2026; generative systems already on the market before that date have until 2 December 2026 to meet the machine-readable marking requirement. The amending act also adds two prohibitions, of AI systems that generate non-consensual intimate imagery of an identifiable person or child sexual abuse material (Art. 5(1)(ba) and (bb) AI Act), which apply from 2 December 2026.

• 13 June 2024: Signed by Parliament and Council Source
• 1 August 2024: Entry into force Source
• 2 February 2025: Prohibitions (Art. 5 AI Act) and AI-literacy duty (Art. 4 AI Act) apply Source
• 2 August 2025: General-purpose AI (GPAI) model obligations, governance and penalties apply Source
• 2 August 2026: Transparency obligations apply (Art. 50 AI Act; not deferred) Source
• 2 December 2026: Marking grace period ends for pre-August-2026 generative systems (Art. 50(2) AI Act) Source
• 2 December 2026: Prohibitions of AI systems that generate non-consensual intimate imagery or child sexual abuse material apply (Art. 5(1)(ba) and (bb) AI Act, inserted by Reg (EU) 2026/1744) Source
• 2 August 2027: Legacy GPAI models must comply (Art. 111(3) AI Act) Source
• 2 December 2027: High-risk obligations for Annex III AI Act systems apply (deferred by Reg (EU) 2026/1744) Source
• 2 August 2028: High-risk obligations for Annex I AI Act product-embedded systems apply (deferred by Reg (EU) 2026/1744) Source

• AI-Enabled Medical Devices: The Regulatory Convergence Problem
• EU AI Act and German Pharma R&D: The 2026–2027 Compliance Cliffs

Regulation (EU) No 536/2014

EU regulation harmonizing clinical trial authorization and supervision through the Clinical Trials Information System (CTIS). The EU Pharma Package, once adopted, would amend it.

• 16 April 2014: Signed by Parliament and Council Source
• 31 January 2022: Date of application Source
• 31 January 2025: Transition complete: all ongoing trials under the CTR in the Clinical Trials Information System (CTIS) Source

• Cross-Border Clinical Trial Agreements: Swiss-EU Coordination Post-Brexit
• Austria's Accelerated Clinical Trial Pathway: What the 35-Day Timeline Does Not Tell US Biotech
• Clinical Trials with Pregnant Participants Under the EU CTR: The Gap Between Permission and Practice
• Clinical Trials with Pregnant Participants in Switzerland, the EU and the US: One Evidence Gap

SR 810.30

Swiss human research act governing research on human diseases and on the structure and function of the human body, conducted with persons, on deceased persons, on embryos and fetuses, or with biological material or health-related personal data.

• 30 September 2011: Adopted by Parliament (final vote) Source
• 1 January 2014: Entry into force Source
• 1 November 2024: Revised ordinances on clinical trials (KlinV) and on human research (HFV) in force; KlinV registration and publication rules (Art. 64–67 KlinV) from 1 March 2025 Source

• Clinical Trials with Pregnant Participants in Switzerland: When Protection Becomes Exclusion

Council first-reading positions ST-7105/26 (Regulation) and ST-7106/26 (Directive)

Overhaul of EU pharmaceutical law that would replace Directive 2001/83/EC and Regulation (EC) No 726/2004, repeal the Orphan and Pediatric Regulations and absorb their rules, and amend (not replace) the ATMP Regulation and the CTR. Council and Parliament reached a provisional agreement in December 2025; in March 2026 Coreper endorsed the compromise text and the Parliament's health committee (SANT) approved it. The Council adopted its position at first reading on 28 September 2026. The Parliament's second-reading vote in plenary (indicatively 23 November 2026) is pending; the acts would then be published in the Official Journal and enter into force on the twentieth day after publication, and their main provisions would apply 24 months after entry into force, around 2028 to 2029. No Official Journal act has been published yet.

• 26 April 2023: Commission proposals (COM(2023) 192 Directive and COM(2023) 193 Regulation) Source
• 11 December 2025: Provisional agreement between Council and Parliament Source
• 6 March 2026: Committee of Permanent Representatives (Coreper) confirmed agreement on the final compromise text Source
• 18 March 2026: Parliament's health committee (SANT) approved the agreed text Source
• 28 September 2026: Council adopted its position at first reading; Parliament's second-reading vote and publication remain pending Source
• 23 November 2026: Parliament plenary vote on the agreed text (indicative) Source

• The 90-Day Rule: How the EU Pharma Package Rewrites Global Filing Strategy for US Sponsors
• The New Orphan Math: Product-Based Exclusivity and What It Does to US Rare-Disease Biotech
• Article 56a of the EU Pharma Package Directive: Access Conditionality and the New Cost of Selective EU Launch
• Bolar at the Border: Expanded Carve-Outs and Earlier Generic and Biosimilar Entry into the EU
• Transferable Exclusivity Vouchers: Will the EU's Antimicrobial Pull Incentive Actually Work for US AMR Developers?
• Environmental Risk Assessment Reaches Across the Pacific: Supply-Chain ERA Obligations for US Manufacturers Using Asian APIs
• Regulatory Sandboxes for Novel Therapies: A New EU Pathway for US Cell, Gene, and AI-Enabled Therapeutics

Directive 2001/83/EC

Current EU code on medicinal products for human use. The EU Pharma Package, once adopted and applicable, would replace it.

• 6 November 2001: Signed by Parliament and Council Source

• Pharma R&D Partnerships: Contractual Risk Allocation
• ATMP GMP Manufacturing: Regulatory Gray Zones Between the EU and Switzerland
• AI in Drug Discovery: Intellectual Property and Data Ownership Challenges

Regulation (EC) No 726/2004

Current EU centralized authorization procedure and EMA framework. The EU Pharma Package, once adopted and applicable, would replace it.

• 31 March 2004: Signed by Parliament and Council Source

• ATMP Hospital Exemption: Where Cell and Gene Therapy Licensing Ends

SR 812.21

Swiss federal therapeutic products act governing medicinal products and medical devices. A third revision is under way in two stages: 3a (digitalization, pediatric medication safety) is in Parliament; 3b (supply security) is in consultation.

• 15 December 2000: Adopted by Parliament (final vote) Source
• 3 September 2025: Federal Council dispatch on revision 3a adopted Source
• 16 October 2026: Revision 3b consultation closes Source

• Swiss Pharma Pricing Under Pressure: What the Three-Year Review Means for R&D Investment
• ATMP Hospital Exemption: Where Cell and Gene Therapy Licensing Ends
• Swiss MedTech Export Without the MRA: What Third-Country Status Requires

COM(2025) 102 (Commission proposal); final compromise text ST-11059/26

EU regulation to secure the supply of critical medicines, agreed but not yet adopted: procurement resilience criteria, contingency stocks and collaborative procurement. Parliament and Council reached a provisional agreement in May 2026, Coreper endorsed the final compromise text on 30 June 2026, and the Parliament's health committee (SANT) approved it on 14 July 2026; the Parliament plenary vote (indicatively 23 November 2026), adoption by the Council and Official Journal publication remain pending.

• 11 March 2025: Commission proposal Source
• 12 May 2026: Provisional agreement between Council and Parliament Source
• 30 June 2026: Coreper endorsed the final compromise text Source
• 14 July 2026: Parliament's health committee (SANT) approved the agreed text Source
• 23 November 2026: Parliament plenary vote on the agreed text (indicative) Source

SR 531

Swiss economic supply-security act: mandatory stockpiles (Pflichtlager) for essential medicines and reporting of supply disruptions, the functional counterpart to the EU's critical-medicines initiative.

• 17 June 2016: Adopted by Parliament (final vote) Source
• 1 June 2017: Totally revised LVG in force Source
• 20 June 2025: Amendment reorganizing the economic supply organization adopted by Parliament (final vote) Source
• 1 November 2025: Amendment in force Source

EudraLex Volume 4, Chapter 4 (Documentation)

Revised GMP documentation chapter; risk-management and data-governance principles, draft under finalization.

• 7 July 2025: Draft published for consultation Source
• 7 October 2025: Consultation closed Source

EudraLex Volume 4, Annex 11 (Computerised Systems)

Major revision of the computerized-systems annex (expanded from 5 to 19 pages); draft under finalization.

• 7 July 2025: Draft published for consultation Source
• 7 October 2025: Consultation closed Source

• EU AI Act and German Pharma R&D: The 2026–2027 Compliance Cliffs
• Nordic NIS2 Enforcement: Five Countries, Two Regimes, and Separate Supervisors for Pharma R&D

EudraLex Volume 4, Annex 22 (Artificial Intelligence)

First GMP annex on artificial intelligence and machine learning (AI/ML) in manufacturing: static, deterministic models for critical GMP applications. The draft excludes generative AI from critical use, an exclusion under review after the June 2026 EMA workshop.

• 7 July 2025: Draft published for consultation Source
• 7 October 2025: Consultation closed Source
• 30 June 2026: European Medicines Agency (EMA) multistakeholder workshop on generative-AI scope Source

AMBV (SR 812.212.1); PIC/S GMP Guide

Switzerland's GMP rules are listed in Annex 1 AMBV under the HMG; they include the EU GMP Guide (EudraLex Volume 4) and the GMP guidelines of the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

• 14 November 2018: Adopted by the Federal Council Source

Directive (EU) 2024/2853

Revised EU product-liability regime covering software, AI systems and digital products. It applies to products placed on the market or put into service after 9 December 2026 and replaces Directive 85/374/EEC, which continues to apply to products placed on the market or put into service before that date.

• 23 October 2024: Signed by Parliament and Council Source
• 8 December 2024: Entry into force Source
• 9 December 2026: Member-State transposition deadline Source

• Pharma Supply Chain Liability: When Contracts Meet Reality
• AI-Enabled Medical Devices: The Regulatory Convergence Problem

SR 221.112.944

Swiss product liability act. Unlike the revised EU PLD, it has not been extended to software and AI, and no revision is pending.

• 18 June 1993: Adopted by Parliament (final vote) Source

• Pharma Supply Chain Liability: When Contracts Meet Reality

Regulation (EC) No 469/2009

EU supplementary protection certificates extending patent-like protection for authorized medicinal products. The 2023 unitary-SPC and recast reform package remains pending in Council.

• 6 May 2009: Signed by Parliament and Council (codified version) Source

• Parallel Imports in Switzerland: Protection Under Pharma Distribution Agreements
• Biotech Licensing: Hidden Contractual Pitfalls

Art. 140a ff. PatG (SR 232.14)

Swiss supplementary protection certificate under the Patentgesetz, mirroring the EU SPC mechanism.

• 3 February 1995: SPC provisions adopted by Parliament (PatG amendment, final vote) Source

• Biotech Licensing: Hidden Contractual Pitfalls

Regulation (EC) No 1394/2007

EU framework for gene-therapy, somatic-cell-therapy and tissue-engineered products. The EU Pharma Package, once adopted, would amend it but not replace it.

• 13 November 2007: Signed by Parliament and Council Source

• ATMP GMP Manufacturing: Regulatory Gray Zones Between the EU and Switzerland
• ATMP Hospital Exemption: Where Cell and Gene Therapy Licensing Ends

SR 810.21; SR 812.21

Switzerland regulates ATMPs functionally rather than in one act: cell- and tissue-based products as transplant products (Transplantatprodukte) under the TxG in conjunction with the HMG, gene-therapy products under the HMG; Swissmedic authorizes both.

• 8 October 2004: TxG adopted by Parliament (final vote) Source
• 1 July 2007: TxG entry into force Source
• 29 September 2023: TxG revision adopted by Parliament Source

• ATMP Hospital Exemption: Where Cell and Gene Therapy Licensing Ends

Regulation (EU) 2024/1938

EU framework on the quality and safety of substances of human origin (blood, tissues, cells) used in humans or to manufacture products, replacing the Blood Directive and the Tissues and Cells Directive.

• 13 June 2024: Signed by Parliament and Council Source
• 6 August 2024: Entry into force Source
• 7 August 2027: Main obligations apply Source
• 7 August 2028: Penalties apply; legacy blood and tissue establishments and their preparations are verified and recorded on the EU SoHO Platform Source

SR 812.21; SR 810.21

Swiss coverage of substances of human origin is split: labile blood and blood products under the HMG, tissues and cells for transplantation under the TxG; no single SoHO-equivalent act exists.

• 8 October 2004: TxG adopted by Parliament (final vote) Source

Regulation (EU) 2021/2282

EU joint clinical assessment of health technologies, applying first to oncology medicines and ATMPs; high-risk medical devices and class D in vitro diagnostics are assessed once the Commission selects them by implementing act.

• 15 December 2021: Signed by Parliament and Council Source
• 12 January 2025: Application begins (oncology / ATMPs first) Source
• 13 January 2028: Joint clinical assessment extends to orphan medicinal products Source
• 13 January 2030: Joint clinical assessment extends to all other medicinal products in its scope (Art. 7(2)(c) HTA Regulation) Source

Regulation (EC) No 141/2000

EU incentives and market exclusivity for orphan medicinal products. The EU Pharma Package, once adopted and applicable, would repeal it and absorb its rules.

• 16 December 1999: Signed by Parliament and Council Source

• The New Orphan Math: Product-Based Exclusivity and What It Does to US Rare-Disease Biotech

Art. 4 Abs. 1 Bst. adecies, Art. 14 Abs. 1 Bst. f, Art. 11b Abs. 4 HMG (SR 812.21)

Swiss orphan regime since 2019: orphan status granted by Swissmedic, simplified authorization, and 15 years of Unterlagenschutz (data exclusivity) under Art. 11b Abs. 4 HMG, unlike the EU's 10-year market exclusivity.

• 18 March 2016: Orphan-drug provisions adopted by Parliament (HMG amendment, final vote) Source
• 1 January 2019: Revised HMG orphan provisions in force Source

Regulation (EC) No 1901/2006

EU framework on medicines for pediatric use. The EU Pharma Package, once adopted and applicable, would repeal it and absorb its rules.

• 12 December 2006: Signed by Parliament and Council Source

Art. 54a ff. HMG; Art. 140n and 140t PatG

Swiss pediatric regime since 2019: pediatric investigation plan duty under Art. 54a ff. HMG, a six-month pediatric extension of the ESZ under Art. 140n PatG, and a standalone pediatric certificate under Art. 140t PatG.

• 18 March 2016: Pediatric provisions adopted by Parliament (HMG and PatG amendment, final vote) Source
• 1 January 2019: Pediatric provisions of the revised HMG and PatG in force Source

SR 232.14; amendment of 15 March 2024 (AS 2026 232)

Swiss patent act. From 1 January 2027 a revised patent-grant procedure applies: the IGE, the Swiss patent office, arranges for a report on the state of the art to be prepared and published (Art. 57a PatG) and, at the request of the applicant or a third party, also examines novelty and inventive step (Art. 58b PatG).

• 25 June 1954: Adopted by Parliament (final vote) Source
• 15 March 2024: Patent-procedure revision passed in the final vote Source
• 1 January 2027: Revised patent-grant procedure in force Source

SR 251

Swiss cartel act. The 2025 partial revision replaces the qualified-dominance test in merger control with the SIEC test (significant impediment to effective competition). The referendum period ended on 17 April 2026 with no referendum announced, and the Federal Council has not yet published the date of entry into force, which it sets. A second bill, reforming the competition authorities, went to Parliament with the Federal Council's dispatch of 20 May 2026.

• 6 October 1995: Adopted by Parliament (final vote) Source
• 19 December 2025: Merger-control revision (SIEC test: significant impediment to effective competition) passed in the final vote Source
• 17 April 2026: Referendum deadline for the merger-control revision Source
• 20 May 2026: Federal Council dispatch on the competition-authorities reform, a second KG bill Source
• 17 September 2026: Implementing-ordinance consultation closed Source

• Swiss Merger Control Adopts the SIEC Test: The Revised Kartellgesetz and US MedTech and Pharma Deals